PHILADELPHIA, May 2, 2011 /PRNewswire/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERT) a global technology-driven provider of services and customizable medical devices to bio-pharmaceutical and healthcare organizations and the market leader for centralized cardiac safety and respiratory efficacy services in drug development, announced today that its Board of Directors has appointed Jeffrey S. Litwin, M.D. its new President and Chief Executive Officer and as a member of the board.
Dr. Joel Morganroth, who had served as interim President and Chief Executive Officer, commented that "after a thorough national search by Heidrick and Struggles, our Board selected Dr. Litwin, an internal candidate, as the most qualified person to lead ERT. Jeff brings to ERT knowledge of the Clinical Research domain, that is our core business, and also experience in the adjacent markets of Phase IV safety surveillance and healthcare in which ERT's assets will be employed. All of our employees look forward to continuing to work with Jeff to enhance ERT's operational successes and strategy."
Dr. Litwin joined ERT in 2000 as Senior Vice President and Chief Medical Officer and was subsequently promoted in December 2005 to Executive Vice President and Chief Medical Officer. Dr. Litwin oversaw ERT's global cardiac safety operations for seven years and was instrumental in implementing EXPERT, ERT's digital operating system. During this time period, ERT experienced tremendous growth with revenues increasing more than three-fold. For the last four years, he has been responsible for leading ERT's consulting business, assisting over 150 companies with the design and evaluation of cardiac safety testing programs. Throughout his career at ERT, Dr. Litwin has also been directly involved in supporting ERT's sales efforts.
In addition to his responsibilitie
|SOURCE eResearchTechnology, Inc.|
Copyright©2010 PR Newswire.
All rights reserved